Autonomic blockade improves insulin sensitivity in obese subjects

Hypertension

Volumn 64, Issue 4, 2014, Pages 867-874

  Gamboa, Alfredo ^a   Okamoto, Luis E ^a   Arnold, Amy C ^a   Figueroa, Rocio A ^a   Diedrich, André ^a,c   Raj, Satish R ^a,b   Paranjape, Sachin Y ^a   Farley, Ginnie ^a   Abumrad, Naji ^a   Biaggioni, Italo ^a,b  

^a VANDERBILT UNIVERSITY   (United States)

^b VANDERBILT UNIVERSITY SCHOOL OF MEDICINE   (United States)

^c VANDERBILT UNIVERSITY   (United States)

Author keywords

Autonomic nervous system; Insulin resistance; Obesity

Indexed keywords

ENZYME INHIBITOR; GANGLION BLOCKING AGENT; GLUCOSE BLOOD LEVEL; INSULIN; N(G) METHYLARGININE; NITRIC OXIDE SYNTHASE; TRIMETAPHAN;

ADULT; ANTAGONISTS AND INHIBITORS; AUTONOMIC NERVOUS SYSTEM; BLOOD; BLOOD PRESSURE; CONTROLLED STUDY; CROSSOVER PROCEDURE; DRUG EFFECTS; FEMALE; GLUCOSE BLOOD LEVEL; GLUCOSE CLAMP TECHNIQUE; HUMAN; INNERVATION; INSULIN RESISTANCE; MALE; METABOLISM; MIDDLE AGED; MUSCLE; OBESITY; PATHOPHYSIOLOGY; PHYSIOLOGY; PROCEDURES; RANDOMIZED CONTROLLED TRIAL;

ADULT; AUTONOMIC NERVOUS SYSTEM; BLOOD GLUCOSE; BLOOD PRESSURE; CROSS-OVER STUDIES; ENZYME INHIBITORS; FEMALE; GANGLIONIC BLOCKERS; GLUCOSE CLAMP TECHNIQUE; HUMANS; INSULIN; INSULIN RESISTANCE; MALE; MIDDLE AGED; MUSCLES; NITRIC OXIDE SYNTHASE; OBESITY; OMEGA-N-METHYLARGININE; TRIMETHAPHAN;

EID: 84914691319     PISSN: 0194911X     EISSN: 15244563     Source Type: Journal    
DOI: 10.1161/HYPERTENSIONAHA.114.03738     Document Type: Article

References (49)

1. Ogden CL, Carroll MD, Curtin LR, McDowell MA, Tabak CJ, Flegal KM. Prevalence of overweight and obesity in the United States, 1999- 2004. JAMA. 2006;295: 1549-1555.
2. Mokdad AH, Marks JS, Stroup DF, Gerberding JL. Actual causes of death in the United States, 2000. JAMA. 2004;291: 1238-1245.
3. Mokdad AH, Marks JS, Stroup DF, Gerberding JL. Correction: Actual causes of death in the United States, 2000. JAMA. 2005;293: 293-294.
4. Olefsky J, Reaven GM, Farquhar JW. Effects of weight reduction on obesity. Studies of lipid and carbohydrate metabolism in normal and hyperlipoproteinemic subjects. J Clin Invest. 1974;53: 64-76.
5. Blüher M. Are there still healthy obese patients? Curr Opin Endocrinol Diabetes Obes. 2012;19: 341-346.
6. Grassi G, Esler M. How to assess sympathetic activity in humans. J Hypertens. 1999;17: 719-734.
7. Flaa A, Aksnes TA, Kjeldsen SE, Eide I, Rostrup M. Increased sympathetic reactivity may predict insulin resistance: An 18-year follow-up study. Metabolism. 2008;57: 1422-1427.
8. Lembo G, Capaldo B, Rendina V, Iaccarino G, Napoli R, Guida R, Trimarco B, Saccá L. Acute noradrenergic activation induces insulin resistance in human skeletal muscle. Am J Physiol. 1994;266(2 Pt 1): E242-E247.
9. Rocchini AP, Mao HZ, Babu K, Marker P, Rocchini AJ. Clonidine prevents insulin resistance and hypertension in obese dogs. Hypertension. 1999;33(1 Pt 2): 548-553.
10. Straznicky NE, Lambert EA, Lambert GW, Masuo K, Esler MD, Nestel PJ. Effects of dietary weight loss on sympathetic activity and cardiac risk factors associated with the metabolic syndrome. J Clin Endocrinol Metab. 2005;90: 5998-6005.
11. Lind L, Eriksson M. Influence of nervous blockade on insulin-mediated glucose uptake in the human forearm. Metabolism. 2003;52: 413-417.
12. May M, Ahrens J, Menne J, Haller H, Beige J, Eckert S, Jordan J, Engeli S. Limited acute influences of electrical baroreceptor activation on insulin sensitivity and glucose delivery: A randomized, double-blind, cross-over clinical study. [published online ahead of print March 19, 2014]. Diabetes. doi: 10.2337/db13-1651 1939-327X.
13. Harris PA, Lane L, Biaggioni I. Clinical research subject recruitment: The volunteer for vanderbilt research program http: //www.Volunteer. Mc.Vanderbilt.Edu. J Am Med Inform Assoc. 2005;12: 608-613.
14. DeFronzo RA, Tobin JD, Andres R. Glucose clamp technique: A method for quantifying insulin secretion and resistance. Am J Physiol. 1979;237: E214-E223.
15. Abumrad NN, Rabin D, Diamond MP, Lacy WW. Use of a heated superficial hand vein as an alternative site for the measurement of amino acid concentrations and for the study of glucose and alanine kinetics in man. Metabolism. 1981;30: 936-940.
16. Diedrich A, Jordan J, Tank J, Shannon JR, Robertson R, Luft FC, Robertson D, Biaggioni I. The sympathetic nervous system in hypertension: Assessment by blood pressure variability and ganglionic blockade. J Hypertens. 2003;21: 1677-1686.
17. Biaggioni I, Killian TJ, Mosqueda-Garcia R, Robertson RM, Robertson D. Adenosine increases sympathetic nerve traffic in humans. Circulation. 1991;83: 1668-1675.
18. Gamboa A, Shibao C, Diedrich A, Choi L, Pohar B, Jordan J, Paranjape S, Farley G, Biaggioni I. Contribution of endothelial nitric oxide to blood pressure in humans. Hypertension. 2007;49: 170-177.
19. Task-Force S. Heart rate variability: Standards of measurement, physiological interpretation and clinical use. Task force of the European Society of Cardiology and the North American Society of Pacing and Electrophysiology. Circulation. 1996;93: 1043-1065.
20. Oppenheim AV, Schafer RW. Digital Signal Processing. Englewood Cliffs, NJ: Prentice-Hall; 1996.
21. Pagani M, Montano N, Porta A, Malliani A, Abboud FM, Birkett C, Somers VK. Relationship between spectral components of cardiovascular variabilities and direct measures of muscle sympathetic nerve activity in humans. Circulation. 1997;95: 1441-1448.
22. Akselrod S, Gordon D, Madwed JB, Snidman NC, Shannon DC, Cohen RJ. Hemodynamic regulation: Investigation by spectral analysis. Am J Physiol. 1985;249(4 Pt 2): H867-H875.
23. Parlow J, Viale JP, Annat G, Hughson R, Quintin L. Spontaneous cardiac baroreflex in humans. Comparison with drug-induced responses. Hypertension. 1995;25: 1058-1068.
24. Jacob G, Robertson D, Mosqueda-Garcia R, Ertl AC, Robertson RM, Biaggioni I. Hypovolemia in syncope and orthostatic intolerance role of the renin-angiotensin system. Am J Med. 1997;103: 128-133.
25. Tam CS, Xie W, Johnson WD, Cefalu WT, Redman LM, Ravussin E. Defining insulin resistance from hyperinsulinemic-euglycemic clamps. Diabetes Care. 2012;35: 1605-1610.
26. Yokoe H, Yuasa F, Yuyama R, Murakawa K, Miyasaka Y, Yoshida S, Tsujimoto S, Sugiura T, Iwasaka T. Effect of pioglitazone on arterial baroreflex sensitivity and sympathetic nerve activity in patients with acute myocardial infarction and type 2 diabetes mellitus. J Cardiovasc Pharmacol. 2012;59: 563-569.
27. Alvarez GE, Beske SD, Ballard TP, Davy KP. Sympathetic neural activation in visceral obesity. Circulation. 2002;106: 2533-2536.
28. Anderson EA, Hoffman RP, Balon TW, Sinkey CA, Mark AL. Hyperinsulinemia produces both sympathetic neural activation and vasodilation in normal humans. J Clin Invest. 1991;87: 2246-2252.
29. Grassi G, Seravalle G, Cattaneo BM, Bolla GB, Lanfranchi A, Colombo M, Giannattasio C, Brunani A, Cavagnini F, Mancia G. Sympathetic activation in obese normotensive subjects. Hypertension. 1995;25(4 Pt 1): 560-563.
30. Gamboa A, Okamoto LE, Diedrich A, Choi L, Robertson D, Farley G, Paranjape S, Biaggioni I. Sympathetic activation and nitric oxide function in early hypertension. Am J Physiol Heart Circ Physiol. 2012;302: H1438-H1443.
31. Shibao C, Gamboa A, Diedrich A, Ertl AC, Chen KY, Byrne DW, Farley G, Paranjape SY, Davis SN, Biaggioni I. Autonomic contribution to blood pressure and metabolism in obesity. Hypertension. 2007;49: 27-33.
32. Bock G, Chittilapilly E, Basu R, Toffolo G, Cobelli C, Chandramouli V, Landau BR, Rizza RA. Contribution of hepatic and extrahepatic insulin resistance to the pathogenesis of impaired fasting glucose: Role of increased rates of gluconeogenesis. Diabetes. 2007;56: 1703-1711.
33. Hunt DG, Ivy JL. Epinephrine inhibits insulin-stimulated muscle glucose transport. J Appl Physiology (1985). 2002;93: 1638-1643.
34. Vollenweider P, Randin D, Tappy L, Jéquier E, Nicod P, Scherrer U. Impaired insulin-induced sympathetic neural activation and vasodilation in skeletal muscle in obese humans. J Clin Invest. 1994;93: 2365-2371.
35. Baron AD, Steinberg HO, Chaker H, Leaming R, Johnson A, Brechtel G. Insulin-mediated skeletal muscle vasodilation contributes to both insulin sensitivity and responsiveness in lean humans. J Clin Invest. 1995;96: 786-792.
36. Mathias CJ, da Costa DF, Fosbraey P, Christensen NJ, Bannister R. Hypotensive and sedative effects of insulin in autonomic failure. Br Med J (Clin Res Ed). 1987;295: 161-163.
37. Natali A, Ribeiro R, Baldi S, Tulipani A, Rossi M, Venturi E, Mari A, Macedo MP, Ferrannini E. Systemic inhibition of nitric oxide synthesis in non-diabetic individuals produces a significant deterioration in glucose tolerance by increasing insulin clearance and inhibiting insulin secretion. Diabetologia. 2013;56: 1183-1191.
38. Clerk LH, Vincent MA, Jahn LA, Liu Z, Lindner JR, Barrett EJ. Obesity blunts insulin-mediated microvascular recruitment in human forearm muscle. Diabetes. 2006;55: 1436-1442.
39. Straznicky NE, Nestel PJ, Esler MD. Autonomic nervous system: Metabolic function. Elsevier; 2009: 951-959.
40. McCubbin JW, Page IH. Nature of the hypotensive action of a thiophanium derivative (Ro 2-2222) in dogs. J Pharmacol Exp Ther. 1952;105: 437-442.
41. Page IH, McCubbin JW. Increased resistance to autonomic ganglionic blockade by tetraethylammonium chloride and pentamethonium iodide in experimental neurogenic hypertension. Am J Physiol. 1952;168: 208-217.
42. Castro-Tavares J. Direct effects of trimetaphan on the dog mesenteric artery and saphenous vein. Br J Anaesth. 1980;52: 769-771.
43. Shannon JR, Jordan J, Diedrich A, Pohar B, Black BK, Robertson D, Biaggioni I. Sympathetically mediated hypertension in autonomic failure. Circulation. 2000;101: 2710-2715.
44. Chazova I, Almazov VA, Shlyakhto E. Moxonidine improves glycaemic control in mildly hypertensive, overweight patients: A comparison with metformin. Diabetes Obes Metab. 2006;8: 456-465.
45. Mahfoud F, Schlaich M, Kindermann I, Ukena C, Cremers B, Brandt MC, Hoppe UC, Vonend O, Rump LC, Sobotka PA, Krum H, Esler M, Böhm M. Effect of renal sympathetic denervation on glucose metabolism in patients with resistant hypertension: A pilot study. Circulation. 2011;123: 1940-1946.
46. Brinkmann J, Heusser K, Schmidt BM, Menne J, Klein G, Bauersachs J, Haller H, Sweep FC, Diedrich A, Jordan J, Tank J. Catheter-based renal nerve ablation and centrally generated sympathetic activity in difficultto- control hypertensive patients: Prospective case series. Hypertension. 2012;60: 1485-1490.
47. Bhatt DL, Kandzari DE, O'Neill WW, D'Agostino R, Flack JM, Katzen BT, Leon MB, Liu M, Mauri L, Negoita M, Cohen SA, Oparil S, Rocha- Singh K, Townsend RR, Bakris GL; SYMPLICITY HTN-3 Investigators. A controlled trial of renal denervation for resistant hypertension. N Engl J Med. 2014;370: 1393-1401.
48. Okada Y, Jarvis SS, Best SA, Bivens TB, Adams-Huet B, Levine BD, Fu Q. Chronic renin inhibition lowers blood pressure and reduces upright muscle sympathetic nerve activity in hypertensive seniors. J Physiol. 2013;591(Pt 23): 5913-5922.
49. Biaggioni I. Should we target the sympathetic nervous system in the treatment of obesity-associated hypertension? Hypertension. 2008;51: 168-171.